The urgent need for metallo-ß-lactamase inhibitors: an unattended global threat.
Lancet Infect Dis
; 22(1): e28-e34, 2022 01.
Article
in English
| MEDLINE | ID: covidwho-1305331
ABSTRACT
Due to their superior tolerability and efficacy, ß-lactams are the most potent and prescribed class of antibiotics in the clinic. The emergence of resistance to those antibiotics, mainly due to the production of bacterial enzymes called ß-lactamases, has been partially solved by the introduction of ß-lactamase inhibitors, which restore the activity of otherwise obsolete molecules. This solution is limited because currently available ß-lactamase inhibitors only work against serine ß-lactamases, whereas metallo-ß-lactamases continue to spread, evolve, and confer resistance to all ß-lactams, including carbapenems. Furthermore, the increased use of antibiotics to treat secondary bacterial pneumonia in severely sick patients with COVID-19 might exacerbate the problem of antimicrobial resistance. In this Personal View, we summarise the main advances accomplished in this area of research, emphasise the main challenges that need to be solved, and the importance of research on inhibitors for metallo-B-lactamases amidst the current pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Bacteria
/
Global Health
/
Drug Resistance, Bacterial
/
Beta-Lactams
/
Beta-Lactamase Inhibitors
/
Anti-Bacterial Agents
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Lancet Infect Dis
Journal subject:
Communicable Diseases
Year:
2022
Document Type:
Article
Affiliation country:
S1473-3099(20)30868-9
Similar
MEDLINE
...
LILACS
LIS